A Phase I/II Study of Carboplatin and Etoposide With or Without Obatoclax in Extensive-stage Small Cell Lung Cancer (ES-SCLC)
NCT00682981
Completed
The Phase I portion of this protocol will determine the best phase II dose and schedule of obatoclax with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. The Phase II portion will evaluate the response rate to this regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/19/2016
Locations: McLeod Cancer & Blood Center, Johnson City, Tennessee +1 locations
Conditions: Extensive-stage Small Cell Lung Cancer
Register for Updates
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
NCT00033696
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining chemotherapy and radiation therapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and radiation therapy in treating patients who have limited-stage small cell lung cancer.
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/15/2016
Locations: University of Tennessee Cancer Institute, Memphis, Tennessee +1 locations
Conditions: Lung Cancer
Register for Updates
Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer
NCT00003117
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of paclitaxel with or without carboplatin in treating patients who have recurrent, stage IIIB, or stage IV non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/28/2016
Locations: University of Tennessee, Memphis Cancer Center, Memphis, Tennessee
Conditions: Lung Cancer
Register for Updates
Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer
NCT00686959
Completed
This study will compare the overall survival of participants with locally-advanced, Stage III Non-Small Cell Lung Cancer (NSCLC) with nonsquamous cell histology.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2016
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chattanooga, Tennessee +2 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
NCT00762034
Completed
This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2015
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Knoxville, Tennessee +1 locations
Conditions: Non-small Cell Lung Cancer
Register for Updates
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
NCT00927589
Completed
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with HER2-positive metastatic or locally advanced inoperable cancer. The QT interval is a measure of time between the start of the Q wave and the end of the T wave in the heart's electrical cycle. The QTcF interval is the QT interval as calculated using Fridericia's correction; the Q... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/05/2015
Locations: Not set, Memphis, Tennessee +1 locations
Conditions: Solid Cancers
Register for Updates
S0200 Carboplatin With or Without Doxil in Patients With Recurrent Ovarian Cancer
NCT00043082
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if carboplatin is more effective with or without liposomal doxorubicin in treating recurrent ovarian epithelial or primary peritoneal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of carboplatin with or without liposomal doxorubicin in treating patients who have recurrent o... Read More
Gender:
FEMALE
Ages:
Between 18 years and 120 years
Trial Updated:
10/23/2015
Locations: University of Tennessee Cancer Institute at Methodist Central Hospital, Memphis, Tennessee +1 locations
Conditions: Ovarian Cancer, Peritoneal Cavity Cancer
Register for Updates
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
NCT00850577
Terminated
The purpose of this study is to determine the efficacy of CT-322 comparative to bevacizumab, both in combination with carboplatin and paclitaxel in the treatment of chemonaive subjects with recurrent or advanced non-squamous NSCLC
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2015
Locations: Cancer Center At Cookeville Regional Medical Center, Cookeville, Tennessee +1 locations
Conditions: Non-small Cell Lung Cancer (NSCLC)
Register for Updates
Study of Neoadjuvant Carboplatin, Eribulin and Trastuzumab for Operable HER2 Positive Breast Cancer
NCT01388647
Terminated
This study will evaluate the safety and efficacy of eribulin in combination with carboplatin and trastuzumab in the neoadjuvant setting in subjects who are human epidermal growth factor receptor (HER)2 positive and are clinically stage IIA to IIIB. The study regimen will be administered every 3 weeks for a total of 6 cycles followed by definitive surgery.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/30/2015
Locations: The West Clinic, Memphis, Tennessee
Conditions: HER-2 Positive Breast Cancer
Register for Updates
Trial of Poor Performance Status Patients (ToPPS)
NCT00892710
Completed
The purpose of this trial is to evaluate three treatment regimens in patients with stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) with a performance status of 2 and who were not previously treated.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2015
Locations: Chattanooga Oncology Hematology Associates, Chattanooga, Tennessee +2 locations
Conditions: Non Small Cell Lung Cancer
Register for Updates
Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer
NCT00254891
Terminated
To assess the efficacy and safety of PF-3512676 administered in combination with paclitaxel/carboplatin chemotherapy as first-line treatment in patients with locally advanced or metastatic Non-Small-Cell Lung Cancer (NSCLC) and to compare it to the efficacy and safety of paclitaxel
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/10/2015
Locations: Pfizer Investigational Site, Chattanooga, Tennessee +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Second-Line Treatment for Patients With Platinum-Sensitive Ovarian Cancer
NCT00090610
Completed
The purpose of this study is to compare the progression-free survival of two treatment regimens for relapsed ovarian cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
02/05/2015
Locations: The West Cancer Clinic, Memphis, Tennessee
Conditions: Ovarian Cancer
Register for Updates